X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The fundings will be used for the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC), the most prevalent type of lung cancer in the United States.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Traverse Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 18, 2023
Details:
The agreement aims to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564, a fully human monoclonal antibody, distinguishes itself from currently available anti-CTLA-4 drugs.
Lead Product(s): GIGA-564
Therapeutic Area: Oncology Product Name: GIGA-564
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: GigaGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 28, 2023
Details:
The Company intends to use the funds for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.
Lead Product(s): Bria-OTS
Therapeutic Area: Oncology Product Name: Bria-OTS
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: BriaCell Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 16, 2023
Details:
The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.
Lead Product(s): CMV-MVA Triplex Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Triplex
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Helocyte
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2023
Details:
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515, a first-in-class deoxycytidine kinase inhibitor, in solid tumors.
Lead Product(s): TRE-515
Therapeutic Area: Oncology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Trethera
Deal Size: $2 million Upfront Cash: Undisclosed
Deal Type: Funding May 30, 2023
Details:
BC2059 (tegavivint) is a first-in-class small molecule inhibitor of Transducin beta-like protein 1 (TBL1), it is being investigated in patients with c-Myc-overexpressing relapsed or refractory large B-Cell lymphomas.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Iterion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
The funding will be used to investigate pharmacodynamic biomarkers for ST316, a first-in-class beta-catenin antagonist, and evaluate the impact of ST316 on the tumor microenvironment (TME) in patient-derived cancer models.
Lead Product(s): ST316
Therapeutic Area: Oncology Product Name: ST316
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Sapience Therapeutics
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 04, 2023
Details:
Tri-Ad5 targets three tumor-associated antigens, brachyury, CEA and mucin-1. It elicits cytotoxic T cell-mediated tumor cell death and the establishment of memory T cells, providing protection against the growth and metastasis of cancer in combination with N-803.
Lead Product(s): Tri-Ad5,Nogapendekin alfa Inbakicept
Therapeutic Area: Oncology Product Name: Tri-Ad5
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: ImmunityBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
The companies will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors in T cell-based Therapy.
Lead Product(s): T cell-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Medigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
Under the licensing agreement, Eureka will develop and commercialize a novel antibody targeting MSLN, a potentially transformative T-cell therapy for solid tumors, in combination with ARTEMIS® T-cell receptor platform.
Lead Product(s): T-cell based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eureka Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
